Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) is a publicly traded Healthcare sector company. As of May 21, 2026, RANI trades at $1.07 with a market cap of $97.14M and a P/E ratio of -3.78. RANI moved +0.00% today. Year to date, RANI is -19.85%; over the trailing twelve months it is +45.51%. Its 52-week range spans $0.39 to $3.87. Analyst consensus is strong buy with an average price target of $7.00. Rallies surfaces RANI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rani Therapeutics Secures $1.7M Q1 Revenue, Extends Cash Runway to Q4 2027: Rani ended Q1 with $43.4M in cash and securities, down from $49.7M, and reported $1.7M contract revenue vs $0.2M a year earlier, projecting funding into Q4 2027. The company advanced its Phase 1 RT-114 obesity trial and appointed three senior leaders while initiating a CFO succession.
| Metric | Value |
|---|---|
| Price | $1.07 |
| Market Cap | $97.14M |
| P/E Ratio | -3.78 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.87 |
| 52-Week Low | $0.39 |
| Volume | 91.96K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.17M |
| Net Income | $-36.23M |
| Gross Margin | 0.00% |
3 analysts cover RANI: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.00.